In conclusion, alongside this explorative study, future in-depth investigations are needed to further elucidate the specific clinical value of ENO1 in EC, in consideration of its possible utility in delineating a population of patients with BE at high risk of cancer, and representing a new therapeutic target to counteract the growth and progression of this aggressive tumor. This evidence concerns the gene ENO1 and cancer.